ALLUVI: A THOROUGH DIVE INTO THE MEDICATION'S POTENTIAL

Alluvi, initially dubbed LY3414901, represents a exciting advancement in metabolic management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist shows remarkable efficacy in early clinical data, with considerable reduction in w